Endpoints News

Pfizer partners with molecular glue startup TRIANA Biomedicines in multi-target protein degrader deal worth $49M upfront and more than $1.5B in milestones. I talked to Triana CEO Patrick Trojer, PhD to learn more about the startup's approach. Read more in my story for Endpoints News: https://lnkd.in/ekMZw3V8 #molecularglue #molecularglues #proteindegrader #proteindegraders #inducedproximity #cancer #oncology #biotech #pharma

? EXCLUSIVE?Nuclera raises $75M for protein manufacturing tech “This is a perfect time to start thinking about making proteins because you just saw the Nobel Prize with David Baker and DeepMind. That increases the demand for making proteins,” CEO Michael Chen told Endpoints News in an interview. Nuclera has developed a microwave-sized platform, dubbed eProtein Discovery, that can be used to make proteins for discovery and research. According to the company, it can make proteins in 48 hours, compared to other traditional methods like liquid handling, which can take months or years. Read more: https://lnkd.in/ewtniwBA

I'm beyond excited for this Wednesday for Endpoints News' first-ever AI Day. The reaction has been astounding — we already have over 3,600+ attendees who have signed up. Save your spot now by registering at the link below. Best of all, this is free and virtual. And it will be well worth the time of anyone interested in better understanding AI, biology, and the future of the biopharma industry. I'll kick things off by going one-on-one with protein design pioneer — and newly minted Nobel laureate — David Baker. I'll also moderate panels that include the full range of people to know in this world, from big pharma leaders like Amgen's Sean Bruich (he/him), to biotech execs like Inceptive's Jakob Uszkoreit and Generate:Biomedicines' Alexandra Snyder, MD to AI scientists in Xaira Therapeutics' Joe Watson, EvolutionaryScale's Alex Rives, and Princeton University's Ellen Zhong. Check out the full agenda below, register for free, and see you this Wednesday:

Exclusive for Endpoints News: British startup Shift Bioscience raises $16M seed funding to find genes that rewind epigenetic clock and rejuvenate aging cells, with help from AI cell simulations. It's a big step up from the company's humble origins, when the young CEO-scientist Daniel Ives spent money from his own bank account to run experiments. https://lnkd.in/euCCaw37 #aging #rejuvenation #healthspan #longevity #epigenetic #epigeneticclock #AI #biotech

Lundbeck has inked its first acquisition in five years as the Danish drugmaker is splashing $2.6 billion for California biotech Longboard Pharmaceuticals, an Arena spinout that entered Phase 3 last month for certain forms of epilepsy, including Dravet syndrome and Lennox Gastaut syndrome. “What we liked about it is its breakthrough designation from the FDA so it really has the differentiation potential in patient populations where there’s still very high unmet need,” CEO Charl van Zyl told Endpoints News in an interview Monday morning. He said Lundbeck has "ascribed no value" to Longboard's second asset, the Phase 1-stage S1P receptor modulator LP659. “I don’t believe that we will stop here, but today we need to digest what we have, fundamentally make sure that we have a very smooth transition once the clearance has been given,” the CEO said. “But we will continue to scout as part of our process of continuing to look at what else we would bring into the long-term pipeline.” #pharma #biotech #manda #biotechacquisition #epilepsy #dravetsyndrome #lennoxgastaut

Jasper Therapeutics’ anti-c-KIT antibody has shown promise in a Phase 1b/2a test in people with certain irritable skin conditions, sending its shares rising on Monday.

Last week was a busy one in the world of biopharma: - Starboard Value took a $1 billion stake in Pfizer this week; - We announced our 20 Women in Biopharma; - Nobel Prizes highlighted the era of AI in biotech; - Judo Bio launched with $100M to target kidneys Want to get the top headlines of the week each Saturday? Sign up to Endpoints Weekly. https://lnkd.in/eZ73fdzr

After a week in which it began a showdown with an activist investor, was betrayed by and then reunited with two former top executives, and ended work on an RSV drug —Pfizer finally has some good, straightforward news. TGIF ???? https://lnkd.in/ezasX9aX

Join us on October 20th at HLTH for our partner program, What’s Working — and What’s Not — in Direct-to-Consumer Care. Register with code EndpointsNe150 to save $250 on your ticket. More info on our partner program below. https://lnkd.in/ehHqAQwb #HLTH #HealthcareInnovation #BeBold